Riskpilot← Back to searchSign inGet full accessK-medical AB
ABActiveOrg 5568026206Drottning Kristinas Väg 1Retail sale of pharmaceutical products · NACE 4773Est. 20101 employees
Revenue 2024
SEK 144K
EBITDA margin
-348.6%
+55% vs 2023
Equity ratio
1.3%
Financial strength
Net profit 2024
SEK 5,1M
+154% vs 2023
| Revenue | SEK 144K | — |
| EBITDA | SEK -502K | +55% |
| Net profit | SEK 5,1M | +154% |
| Total assets | SEK 19,4M | +8% |
| Equity | SEK 248K | +105% |
| Employees | 1 | — |
Legal name
K-medical AB
Org number
5568026206
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
20 mars 2010
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget har till föremål för sin verksamhet att förvalta aktier i bolag som bedriver apoteksverksamhet samt att, direkt eller indirekt, äga och förvalta övrig fast och lös egendom och därmed förenlig verksamhet.
Address
Drottning Kristinas Väg 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 287 | 0 | 5 | 0 | 144 |
| Staff expenses | — | — | −955 | −834 | — |
| EBITDA | −538 | −832 | −1 030 | −1 111 | −502 |
| Depreciation & amort. | −0 | −0 | — | — | −0 |
| EBIT | −538 | −832 | −1 030 | −1 111 | −502 |
| Net financials | −11 196 | −9 542 | −5 459 | −10 968 | 4 707 |
| Profit before tax | −5 990 | −3 872 | −4 990 | −9 220 | 5 125 |
| Tax | −0 | −0 | −8 | −282 | −17 |
| Net profit | −5 990 | −3 872 | −4 997 | −9 501 | 5 108 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 26 244 | 28 574 | 28 389 | 17 936 | 19 353 |
| Equity | 13 511 | 9 639 | 4 641 | −4 860 | 248 |
| Long-term debt | 6 005 | 6 385 | 10 395 | 6 210 | 4 055 |
| Short-term debt | 6 728 | 12 550 | 13 352 | 16 586 | 15 050 |
| Total debt | 12 733 | 18 935 | 23 747 | 22 796 | 19 105 |
EBITDA margin
-348.6%
This company
15.8%
Market median
-2306% vs market
20202024
Equity ratio
1.3%
This company
38.2%
Market median
-97% vs market
20202024
Return on equity
2059.7%
This company
18.4%
Market median
+11094% vs market
20202024
Net profit margin
3547.2%
This company
8.1%
Market median
+43693% vs market
20202024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20202024
Debt / equity
77.04×
This company
0.62×
Market median
-12326% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EG Audit | Audit | 2025 |
| Former (1) | ||
LM Chief Auditor | Chief Auditor | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
K-medical AB 
Apoteksgruppen i Stockholm Nr 2 ABBoard members of K-medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Michael Magnusson | Chief Auditor | 0 companies |
| Erik Gunnar Ågerup | Audit | 0 companies |
| Mir Mohammad Hamed Khalighi | Deputy Board Member | 0 companies |
| Reza Khiabani | Board of Directors | 0 companies |